Dr. Srdan Verstovsek on JAK2 Inhibitors as a Treatment for Myelofibrosis

December 8, 2015
Srdan Verstovsek, MD, PhD

Srdan Verstovsek, MD, PhD, discusses the JAK2 inhibitor, as well as upcoming treatments like momelotinib and pacritinib, for the treatment of patients with myelofibrosis.

Srdan Verstovsek, MD, PhD, chief of the Section of Myeloproliferative Neoplasms, MD Anderson Cancer Center, discusses the JAK2 inhibitor, as well as upcoming treatments like momelotinib and pacritinib, for the treatment of patients with myelofibrosis.

Verstovsek says the JAK2 inhibitor improves quality of life in patients and was approved based on data from a recent phase III trial. He adds that the JAK2 inhibitor is important for myelofibrosis because it is the only approved treatment currently available.

Verstovsek says upcoming JAK2 inhibitors, such as momelotinib and pacritinib, may be able to improve quality of life for patients as well. Both momelotinib and pacritinib are currently undergoing trials.